

4 March 2024

ASX Announcement

Nasodine COVID-19 Patent Allowed in US

- **New US patent extends patent coverage to reduction in SARS-CoV-2 shedding**

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that it has received notice of allowance of a second patent in the US relating to COVID-19.

The new patent specifically protects the use of Nasodine® Nasal Spray (“Nasodine”) and any other intranasal povidone-iodine (PVP-I) preparations containing 0.10-1.25% PVP-I, as a method of decreasing the release of infective SARS-CoV-2 from the nose.

The previously granted patent in the US (refer announcement 17 February 2022) covered the use of any intranasal PVP-I formulations (containing 0.10-1.25% PVP-I) to reduce the viral load of SARS-CoV-2 in the nose. The newly allowed claim valuably extends Nasodine’s protection to include reduction in shedding of infectious virus, which has important implications for reducing the risk of transmission.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (www.firebrickpharma.com). The Company has successfully developed a povidone-iodine nasal spray, called Nasodine® Nasal Spray, and filed international trademarks and multiple patents on the product, including pharmaceutical formulation and use patents. The Company has also completed six clinical trials for the nasal spray, including a Phase 1 study, three Phase 2 studies and two Phase 3 studies, which have affirmed the product’s safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com